FSNUF
Fresenius SE & Co. KGaA
- PER (TTM)
- 17.25
- PER (Forward)
- 15.44
- EPS (TTM)
- -
- EPS (Forward)
- -
- PBR
- 1.31
- 시가총액
- 30.61B
- 배당수익률
- 227.00%
- 베타
- 0.86
- 1개월 수익률
- 0.00%
- 3개월 수익률
- -2.77%
- 6개월 수익률
- 1.12%
- 1년 수익률
- 48.53%
- 2년 수익률
- -
- 5일 평균거래량
- 0
- 60일 평균거래량
- 18
- 1년 평균거래량
- 40
- 5d/60d 거래량 비율
- 0.00×
- 60d/1y 거래량 비율
- 0.46×
- 변동성(60일, 연환산)
- 10.32%
- BB 스퀴즈 스코어
- 0.00
- SMA50 비율
- 1.00
- SMA200 비율
- 1.00
- RSI (14)
- 29
- 20일 수렴도
- 0.00
- 52주 최고
- 58.16
- 52주 최저
- 36.59
- 고점 대비
- -6.55%
- 저점 대비
- 48.53%
펀더멘털 갱신: 2026-05-10T09:03:27+00:00 · 시세 갱신: 2026-05-10T06:35:11+00:00
회사 정보
Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients in North America, Europe, the Asia-Pacific, Latin America, and Africa. It operates through Fresenius Kabi and Fresenius Helios segments. The Fresenius Kabi segment offers products for therapy and care of critically and chronically ill patients, including biopharmaceuticals, clinical nutrition, MedTech products, intravenously administered generic drugs, and IV fluids. It also provides biosimilar drugs; enteral and parenteral nutrition products; and medical technologies that include disposables, infusions pumps, apheresis machines, cell therapy devices, and other products. The Fresenius Helios segment operates hospitals, medical care centers, occupational health centers, prevention centers, and outpatient health centers, as well as provision of medical diagnostics. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is based in Bad Homburg vor der Höhe, Germany.